免疫疗法用于晚期肝癌的一线治疗

StephenW

Immunotherapy for First-Line Treatment of Advanced HCC
Approved First-Line Therapies for Advanced HCC

No immunotherapy has yet been approved for the first-line treatment of patients with HCC. Atezolizumab plus bevacizumab, however, is currently under FDA review for use in this setting.15
First-Line Therapies Under FDA Review for Advanced HCC
Atezolizumab Plus Bevacizumab in the Frontline Setting

Based on findings from the IMbrave150 trial, in which atezolizumab plus bevacizumab produced superior survival outcomes compared with sorafenib, the FDA is currently reviewing the combination therapy, for use in patients with untreated, inoperable HCC.15,40 In 2018, this combination therapy received breakthrough therapy designation from the FDA based on findings from the phase Ib GO30140 trial (NCT02715531) described below. 41-44 5/29/20 The US FDA has approved atezolizumab in combination with bevacizumab for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy.

StephenW

免疫疗法用于晚期肝癌的一线治疗
批准用于高级肝癌的一线疗法

尚未批准将免疫疗法用于HCC的一线治疗。但是，目前在这种情况下使用Atezolizumab加贝伐单抗进行FDA审查15。
FDA审查的晚期HCC一线疗法
前线环境中的Atezolizumab加Bevacizumab

根据IMbrave150试验的发现，其中atezolizumab加bevacizumab较索拉非尼产生更好的生存结果，FDA目前正在审查该联合疗法，以用于未经治疗，无法手术的HCC患者.15,40在2018年，该联合疗法接受了FDA根据以下所述的Ib GO30140期临床试验（NCT02715531）的发现指定了突破性疗法。 41-44 5/29/20美国FDA批准了atezolizumab与bevacizumab的组合治疗未接受过全身治疗的无法切除或转移性HCC的患者。